COVID-19 Vaccine Effectiveness Against the Omicron Variant in a Veterans Affairs Cohort of Patients With Inflammatory Bowel Disease.

"CONFLICTS OF INTEREST Guarantor of the article: Nabeel Khan, MD. Specific author contributions: N.K. has participated in study supervision, funding acquisition, study concept and design, acquisition of data, analysis and interpretation of data, drafting of the manuscript, and critical revision of the manuscript for important intellectual content. N.M. has participated in study concept and design, acquisition of data, formal statistical analysis, data visualization and presentation, analysis and interpretation of data, drafting of the manuscript, and critical review of the manuscript for important intellectual content. Financial support: This study was supported by an unrestricted research grant from Pfizer Pharmaceuticals. Pfizer had no role in the study concept and design, acquisition or interpretation of data, statistical analysis, preparation of the manuscript, or critical review of the manuscript. Potential competing interests: N.K. has received an unrestricted research grant from Pfizer, Luitpold, and Takeda Pharmaceuticals as well as Samsung BioEpis. N.M. is supported by an American College of Gastroenterology (ACG) Junior Faculty Development Award (ACG-JR-010-2020) and by the National Institutes of Health (K08-DK-124577-01A1). Data availability statement: The identified data (data with patient identifiers) for this study, which was used to obtain data from patient charts, cannot be made available as per HIPAA guidelines. However, deidentified data can be made available on request."

"Financial support: This study was supported by an unrestricted research grant from Pfizer Pharmaceuticals. Pfizer had no role in the study concept and design, acquisition or interpretation of data, statistical analysis, preparation of the manuscript, or critical review of the manuscript."